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The binding of endothelin (ET) to human placenta ET receptor was strongly inhibited by cadmium ions (Cd2+) (IC,, -2 x 10-s M). Experiments 
with affinity cross-linking showed that the major 40 kDa receptor was inhibited to form a [12sI]ET-1/receptor complex. The mode of inhibition 
was noncompetitive with respect to ET-l. The inhibitory effect of Cd*+ on solubilized ET receptor was partially reversed by the chelating agent, 
ethylenedinminetetraacetic a id (EDTA), whereas the effect was irreversible for the membrane-associated receptor. The rat aorta contractions by 
ET were prevented by pretreatment or addition of Cd*+. 
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1. INTRODUCTION 
Endothelin (ET) is a potent vasoconstrictive peptide 
produced by endothelial cells of blood vessels [ IS!]. The 
pressor response of ET is largely ascribable to its 
vasoconstrictive activity /l-7]. This activity is greater 
than that of any other known vasoconstrictors of mam- 
malian origin including human tissue and is apparently 
correlated with the high affinity of endothelin to its 
receptor. The action of ET has been shown to increase 
the intracellular calcium (Ca”) concentration [1,2]. 
Specific binding sites for ET have been detected in 
various animal cells and tissues [f&13]. The 40 kDa 
receptor which we have previously solubilized and 
purified from human placenta is one of them [14]. In 
this study, the effects of cadmium (Cd”) ion on the 
binding of ET to receptor and the rat aorta contraction 
induced by ET were investigated. 
2. MATERIALS AND METHODS 
2. I . Materials 
Human ET-l, ET-2 and ET-3 were purchased from Peptide In- 
stitute Inc. (Osaka, Japan), and ‘2-CI-labeled ET-I (spec. act. 62 
Tbq/mmol) was from Amersham. All other reagents were of 
analytical grade. Divalent metals used in the present experiments are 
all in chloride form. 
2.2. Preparaiiott of endo(helin receptor 
Human placenta membrane was prepared by the method described 
previously (141. For preparation of solubilized receptor, it was 
homogenized with 50 mM HEPES (N-(2_hydroxyethyl)piperazine- 
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N’-(2-ethanesulfonic acid)) buffer (pH 7.4) containing 0.6% 
zwitterionic detergent CHAPS (3-[(3-cholamidopropyl)]dimethylam- 
monio-propane sulfonic acid), 0.6 M NaCI and 0.5 mM phenyl- 
methylsulfonyl fluoride (PMSF). The ET receptor was salubilized by 
stirring the mixture overnight at 4°C. The mixture was centrifugated 
at 21 000 x g for 60 min and ET receptor was obtained in the super- 
natant fraction. The solubilized receptor (IO ml) was applied to 
Sephadex G-25 column (1.5 x 40 cm) equilibrated with 50 mM 
HEPES buffer (pH 7.4), 0.1% CHAPS and 0.5 mM PMSF, and the 
fractions containing ET binding activity were pooled. 
2.3. Binding assay 
The binding assay was carried out according to the previous report 
[14] with slight modifications. The reaction mixture (50 ~1) contained 
50 mM HEPES buffer (pH 7.4), 0.1% CHAPS, solubilized ET recep- 
tor (about 2 pg of protein) and 62.5 pM [“sl]ET (- I x 10J cpm). It 
was incubated for 30 min at room temperature (2YC). Nonspecific 
binding was determined by the addition of 500 nM nonradioactive 
ET-l, The receptor [‘2SI]ETcomplex was separated from free [lZ51]ET 
by mixing 50 pl of 15% (v/v) calcium phosphate gel which precipi- 
tated the complex upon centrifugation (15 000 rpm, for 1 min). The 
pellet was washed with 0.3 ml of 50 mM sodium phosphate buffer (pH 
7.4)/0.2% CHAPS, and reprecipitated by centrifugation (15 000 
rpm, 1 min). The radioactivity was counted with a gamma-counter. 
2.4. Cross-linking of [“‘IjET receptor 
An aliquot (IO @I) of the solubilized ET receptor (2 mg protein/ml) 
was incubated for 30 min with 400 pM [‘2SI]ET-I in 50 rtl of 50 mM 
HEPES buffer (pH 7.4) containing 0.1% CHAPS. To the reaction 
mixture was added 0.5 mM disuccinimidyl suberate (DSS) and was 
further incubated for 40 min at room temperature. After addition of 
Tris-HCI (pH 6.8) to final 60 mM, the cross-linked receptor was 
analyzed by 11% polyacrylamide gel electrophoresis in the presence 
of 1% sodium dodecylsulfate (SDS). 
2.5. Vasoconstricrion assay 
Thoracic aortae were isolated from anesthetized male Wistar rats 
(- 200 g). The aortae were cut into helical strips, suspended in Krebs- 
Ringer solution which were maintained at 37°C and gassed with 95% 
02/5% CO2. Tensions, developed by the addition of ET-l. were 
recorded with force/displacement ransducers. 
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3. RESULTS 
Among the various heavy metals tested, Cut+ and 
Cd’+ strongly inhibited the binding of [‘2SI]ET-l to the 
solubilized endothelin receptor from human placenta 
(Ta;y; iI2 ‘+fhe b;lyding was not2 Fhibited by Fe’ + , 
w3 ,Mn’+ orN1 even at high con- 
centrations (;O mM). To know more about the inhibi- 
tion by Cd’ + and Cu2 +, a detailed study was under- 
taken with decreasing concentrations of the two 
divalent cations. The results showed that inhibitory ef- 
fect of Cd’ + on ET-l binding (50% inhibitory concen- 
tration, IGo= 20 PM) was greater than that of Cu2+ 
(200 /.&I). 
We have previously shown that human placenta con- 
tained a major 40 kDa receptor whish was affinity 
labeled by cross-linking with [‘2SI]ET-I, -2, and -3 [14]. 
As shown in Fig. 1, the [‘251]ET-1 cross-linking to 40 
kDa receptor was diminished to about 50% and 90% in 
the presence of 20 PM and 100 PM Cd’+, respectively. 
At the high concentration of 1 mM, Cut+ completely 
inhibited cross-linking. Next, to examine the mode of 
inhibition, a steady-state kinetic study was undertaken 
under the conditions in which the concentration of 
ligand [‘251]ET-1 was varied from 1 to 15 pM (Fig. 2). 
As expected from the nonsaturated condition of bin- 
ding reaction, the ET-l binding increased as the concen- 
tration of [“‘I]ET-1 increased (Fig. 2, control). Upon 
the addition of Cd’+ (10 FM), the same If&s were 
found for all the [‘251]ET-l concentrations tested. 
These results suggested that Cd’+ inhibits the forma- 
tion of ET-l-receptor complex in a noncompetitive 
manner with respect to ET-l. Similar results were ob- 
tained when [“‘I]ET-2 and [‘2SIJET-3 were used as 
ligands (data not shown). 
The effect of a chelating agent on the Cd2+ inhibition 
was examined, particularly to see if the reagent can pre- 
vent the inhibition and reactivate the Cd’+-inactivated 
ET receptors. The experiments were carried out for 
membrane-associated receptor and solubilized recep- 
Table I 
Effect of divalent metal ions on ET-I binding 
Metals (10 mM) Cont. (mM) ET-I binding (070) 
none 100 
Fe IO 100 
Ca 10 91 
Zn 10 85 
Mg 10 77 
Ni 10 73 
co 10 70 
Mn 10 69 
Hg 10 30 
cu 1 11 
0.1 49 
Cd 0.1 7 
0.01 56 
--- 
72 
1mM 20pM IOOpM 
None Cu Cd Cd 
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Fig. I. Affinity labeling of ET receptor with [‘ZsI]ET-I in the presence 
or absence of Cd’ + or Cu’+ . Solubilized ET receptors(20 jrcg protein) 
were labeled by cross-linking with [‘“‘I]ET-1 in the absence (lane 1) or 
presence of the indicated concentrations of CUCIZ (lane 2) or CdClz 
(lane 3,4). DSS (0.5 mM) was used as a cross-linker as reported 
previously [14]. Samples were subjected to SDS-PAGE under non- 
reducing conditions. 
tor. With 0.1 mM Cd2 +, the binding of [‘2SI]ET-l to 
either of the receptors were inhibited by more than 90% 
(Fig. 3). However, when 10 mM EDTA was incubated 
with either of the receptors, no difference in inhibition 
0 rn”llOl 
A Cd(lO!.lM) 
m Cd VOOuM) 0 
lPOO0~ 
0 
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Fig. 2. Binding of solubilized ET receptor to [‘2SI]ET-I in the presence 
or absence of CdClz. Solubilized ET receptor (2 ng) was incubated in 
the mixture as described in the Materials and Methods: no CdClz 
(C--O), 10 FM CdClz (U) or 100 /tM CdClz (M). ET recep- 
tors were assayed at different concentrations of [‘ZSI]ET-I as describ- 
ed in the Materials and Methods. 
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Fig. 3. Effect of EDTA on the Cd *+ inhibition of solubilized and 
membrane-bound ET receptors. Cd + EDTA represents a condition 
in which ET receptors were preincubated with 0.1 mM CdCIz and 10 
mM EDTA. Pretreatment with Cd + EDTA represents experiments 
in which preincubation of ET receptor was performed with 0.1 mM 
CdClz, followed by the addition of 10 mM EDYA. Results are ex- 
pressed as percentage of the binding activities of the control ET recep- 
tors which were incubated in the absence of CdCIz and EDTA. 
was seen, indicating that EDTA could remove Cd2 + ion 
from the reaction mixture and the remaining large ex- 
cess of free EDTA or Cd’+ /EDTA complex did not af- 
fect the binding activity. These results also suggest that 
the free Cd2+ ions bind to receptor molecule and pre- 
vent it to bind [“51]ET-l. Furthermore, in order to 
understand the effect of EDTA on the 
Cd2 + -inactivated receptor, the following experiments 
were carried out. Both the membrane-associated recep- 
tor and the solubilized receptor were first incubated 
with 100 @I CdCl2 for 15 min. 10 mM EDTA was then 
added to the mixture and the binding activity of recep- 
tors was measured to see if EDTA can remove the 
bound Cd2 + from receptor and restore the binding ac- 
tivity. As shown in Fig. 3, EDTA could recover 40-50% 
of binding activity for the solubilized receptors but it 
could not resover the aclivity for the membrane- 
associated receptors. The results indicate that the addi- 
tion of EDTA after preincubation with Cd’+ was total- 
ly ineffective in reversing the Cd2 + -induced inhibition 
of membrane-bound receptors, but was partially effec- 
tive in reversing the inhibition of the solubilized mem- 
branes. 
There are several reports that described a hypotensive 
effect of Cd’+ on experimental animals. To relate the 
present findings of Cd”-induced inhibition of en- 
dothelin p:ceptor to pharmacological hypotension, we 
examined the inhibitory effect of Cd” on rat aorta 
c&traction by endothelin. As reported previously [l], 1 
nM ET-1 induced an increase in the tension of the 
helical strip of aorta, which remained in a state of ten- 
sion for at least 60 min (Fig. 4a). When Cd’+ (100 PM) 
was added, a gradual decrease in the tension occurred 
and, in about 15 min, the tension returned to the basal 
levels. Here, Cd2 + apparently reversed the effect of en- 
dothelin while Cd” by itself does not act as 
vasodilator. Next, when the aorta strip was prein- 
cubated in the medium containing 100 ,uM CdCl2 for 10 
min and when washed and soaked in the new Ringer 
solution containing 1 nM ET-l, the tension increased 
about 30% of the level of the untreated aorta strip. 
Curiously, the tension did not last long and it returned 
to basal levels within the second 60-min incubation 
period (Fig. 4b). 
Cd (100jtM) 
Fig. 4. Effect of CdC12 on contractile responses of rat aortic strips to ET-l. (a) Typical example of ET-1 induced contraction of rat aortic strips 
and the effect of CdC12. (b) A response curve to 1 nM ET-l after treatment with 100 FM CdCIz. 
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4. DISCUSSION 
It has previously been demonstrated that Cd’+ in- 
hibits the contractions of vascular muscles induced by 
noradrenaline, angiotensin and high-K + [ 1 S- 181. 
Recently, a few reports have indicated that Cd* + also 
prevents the contractile action of ET-1 [19-211. Inhibi- 
tion of the inward fluxes of Cazt appeared to be the 
major mechanism responsible for the effect of Cd2 +. 
Therefore, they concluded from these studies that the 
attenuation of the ET-induced contraction by Cd2+ is 
due to a consequence of an inhibitory effect of Cd*+ on 
Ca2 + -channel and/or Na ’ /Ca* + exchange mechan- 
isms. However, the present study has clearly 
demonstrated that Cd’+ interacts with the ET receptor 
and prevents binding to endothelin. Furthermore, we 
find that a 50% inhibition concentration of Cd*+ on 
ET-binding is in agreement with IGO = 15 PM previous- 
ly reported for by attenuation of the maximum 
response to ET- 1 [ 191. These results suggest hat the at- 
tenuation of ET-induced contraction by Cd2 + may be a 
direct action via inhibition of ET-receptor. irreversible 
inhibition of the membrane-associated receptor may be 
due to an allosteric conformational distortion of recep- 
tor molecules resulting from Cd’+ binding to mem- 
branes [18]. 
ET, like other vasoconstricting hormones such as 
phenylepinephrine, angiotensin II and histamine, acts 
on myocytes [ 1,2], but ET appears to mobilize Ca2 + in 
atria1 cells better than the above compounds do. ET has 
been proposed to induce vasoconstriction by acting as 
an endogenous modulator of a dihydropyridine- 
sensitive, voltage-dependent Ca’ + -channel [CL]. On the 
other hand, Vigne et al. [22] reported that the increase 
in Ca*+ concentration induced by ET was due to the 
mobilization of intracellular stores and due to the entry 
of Ca2” into their sarcolemma via a pathway that does 
not utilize voltage-dependent L-Ca2 + channels. Indeed, 
ET stimulates the conversion of phosphatidyl inositol 
into inositol trisphosphate and diacylglycerol which 
mobilize Ca’ + from an intracellular pool, and activates 
protein kinase C, respectively [6,7,23,24]. 
The major role of ET is believed to be involved in the 
regulation of blood pressure and blood flow. Biological 
data suggest hat ET and its receptor system may be in- 
volved in vasospasm and peripheral vasoconstriction 
that result in hypertension, renal failure and/or heart 
failure. 
Our data demonstrate that the Cd’+ ion directly in- 
teracts with the ET receptor and inhibits the binding of 
endothelin. It may, however, be too early to relate this 
effect of Cd” on the inhibition of contraction, since 
Cd2 + apparently inhibits contraction caused by other 
vasoconstrictors. Cd’+ may inhibit various steps of 
signal transduction, the mechanism of which remains to 
be studied. 
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